{"context":{"query":">>hgnc>>gwas","source_dataset":"hgnc","target_dataset":"gwas"},"stats":{"queried":1,"total":39,"mapped":1},"pagination":{"has_next":false},"schema":"id|disease_trait|mapped_gene|chr_id|p_value","mappings":[{"input":"HGNC:11138","source":"HGNC:11138|synuclein alpha","targets":["GCST000528_4|Parkinson's disease|SNCA|4|2.000000e-16","GCST000530_1|Parkinson's disease|SNCA|4|7.000000e-17","GCST000567_6|Parkinson's disease|SNCA|4|7.000000e-08","GCST000772_1|Parkinson's disease|SNCA|4|3.000000e-11","GCST000855_3|Parkinson's disease|SNCA|4|9.000000e-16","GCST000874_1|Parkinson's disease|SNCA|4|3.000000e-08","GCST000959_7|Parkinson's disease|SNCA|4|2.000000e-47","GCST001126_2|Parkinson's disease|SNCA|4|2.000000e-19","GCST001430_2|Parkinson's disease|SNCA|4|8.000000e-35","GCST001445_5|Parkinson's disease|SNCA|4|6.000000e-65","GCST001445_6|Parkinson's disease|SNCA-AS1 - MMRN1|4|5.000000e-11","GCST002353_2|Parkinson's disease|SNCA|4|1.000000e-09","GCST002353_3|Parkinson's disease|SNCA|4|3.000000e-11","GCST002544_19|Parkinson's disease|SNCA|4|4.000000e-73","GCST003800_1|Response to bupropion in depression|GPRIN3 - SNCA|4|3.000000e-08","GCST003922_2|Parkinson's disease|SNCA|4|1.000000e-32","GCST003984_5|Parkinson's disease|SNCA|4|1.000000e-56","GCST004902_48|Parkinson's disease|SNCA|4|5.000000e-123","GCST005276_2|Dementia with Lewy bodies|SNCA|4|9.000000e-13","GCST006585_2238|Blood protein levels|SNCA|4|8.000000e-30","GCST006585_643|Blood protein levels|SNCA|4|1.000000e-09","GCST006940_38|Neurociticism|SNCA|4|2.000000e-10","GCST006948_44|Feeling nervous|SNCA|4|1.000000e-09","GCST007780_1|Parkinson's disease (age of onset)|SNCA|4|2.000000e-12","GCST007780_2|Parkinson's disease (age of onset)|SNCA-AS1|4|7.000000e-06","GCST008477_24|Emphysema annual change measurement in smokers (adjusted lung density)|SNCA|4|7.000000e-06","GCST009325_4|Parkinson's disease or first degree relation to individual with Parkinson's disease|SNCA|4|4.000000e-154","GCST009325_5|Parkinson's disease or first degree relation to individual with Parkinson's disease|SNCA|4|1.000000e-36","GCST009325_93|Parkinson's disease or first degree relation to individual with Parkinson's disease|GPRIN3 - SNCA|4|1.000000e-48","GCST009325_94|Parkinson's disease or first degree relation to individual with Parkinson's disease|SNCA|4|5.000000e-149","GCST009373_1|Parkinson's disease in GBA mutation carriers|SNCA|4|2.000000e-11","GCST009512_1|Parkinson's disease|SNCA|4|2.000000e-09","GCST009513_1|Parkinson's disease (age of onset)|SNCA|4|2.000000e-07","GCST010049_1|Parkinson's disease|SNCA|4|2.000000e-37","GCST010991_37|Parkinson's disease|GPRIN3 - SNCA|4|4.000000e-17","GCST011677_2|Parkinson's disease (age of onset)|SNCA|4|1.000000e-06","GCST012354_9|Anxiety|SNCA|4|4.000000e-11","GCST012431_14|Parkinson's disease|SNCA-AS1|4|9.000000e-10","GCST012431_8|Parkinson's disease|SNCA-AS1|4|6.000000e-09"]}]}